Precision Medicine in Oncology
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Attend An Event
State of the Science Summit
Regional Seminar Series
OncLive Global Expo
Giants of Cancer Care
Precision Medicine in Oncology
<< View More Conferences
2016 ASCO Annual Meeting
Oncology Conference Multimedia
View more videos >>
Frontline Nab-Paclitaxel/Gemcitabine in Metastatic Pancreatic Cancer
Dr. Tempero on the HALO 301 Trial for Pancreatic Cancer
Dr. Reidy-Lagunes on Sequencing Therapies for Patients With NETs
Oncology Conference Articles
Dr. Strosberg on the Results of the NETTER-1 Trial
Jonathan Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the results of the NETTER-1 trial.
Abiraterone Regimen Demonstrates Safety, Activity in CRPC
A combination regimen involving abiraterone acetate (Zytiga) and low-dose prednisone demonstrated a median time to radiographic progression of 41.4 months, as well as a median time to prostate-specific antigen progression of 28.7 months, in men with nonmetastatic castration-resistant prostate cancer.
T-VEC/Pembrolizumab Combo Shows Early Promise in Advanced Melanoma
The combination of the oncolytic virus talimogene laherparepvec (T-VEC) and pembrolizumab (Keytruda) demonstrated evidence of clinical benefit, as well as an acceptable safety profile, in patients with advanced melanoma.
Pembrolizumab Shows Robust Activity in Head and Neck Cancer
Pembrolizumab demonstrated an objective response rate of 18% in data from two clinical trials exploring the PD-1 inhibitor as a treatment for patients with pretreated recurrent or metastatic head and neck squamous cell carcinoma.
Survival Benefit Observed With Olaparib in Ovarian Cancer
In patients with platinum-sensitive relapsed serous ovarian cancer, olaparib (Lynparza) was found to significantly increase overall survival when given as maintenance therapy.
Process Unclear on How to Identify Mutations in Non-Lynch Syndrome Patients With CRC
Results of an analysis presented at the 2016 ASCO Annual Meeting demonstrate the difficulty in determining the prevalence of germline cancer susceptibility gene mutations in patients with colorectal cancer (CRC) who do not harbor Lynch syndrome.
Electric Field Treatment Shows Early Efficacy, Safety in Frontline Pancreatic Cancer
A device using tumor treating fields that was administered to patients with unresectable pancreatic cancer showed early signs of tolerability and safety when in combination with gemcitabine in the frontline setting.
Cabozantinib Improves Survival in Renal Cell Carcinoma
Cabozantinib reduced the risk of death by 34% compared with everolimus in patients with previously treated advanced renal cell carcinoma, according to updated data from the phase III METEOR trial.
CAR Therapy Achieves Durable Responses in Refractory Lymphoma
Three-fourths of patients with advanced lymphoma achieved durable objective responses to treatment with chimeric antigen receptor T-cell therapy targeting CD19 even after a low-dose chemotherapy conditioning regimen.
Pembrolizumab/Bevacizumab Combo Passes Safety Test in Recurrent Glioblastoma
An immunotherapy/antiangiogenesis combination proved to be safe and tolerable for patients with recurrent glioblastoma, preliminary data from an ongoing trial showed.
Avelumab Highly Effective in Metastatic Merkel Cell Carcinoma
The PD-L1 inhibitor avelumab demonstrated durable responses and promising early survival data for patients with pretreated metastatic Merkel cell carcinoma.
High Response Rates Achieved with Pembrolizumab in Refractory Hodgkin Lymphoma
Pembrolizumab (Keytruda) is associated with an exceptional overall response rate in patients with relapsed/refractory Hodgkin lymphoma.
Impressive Upfront Palbociclib PFS Benefit Confirmed in ER+/HER2- Breast Cancer
Adding the CDK 4/6 inhibitor palbociclib (Ibrance) to letrozole reduced the risk of disease progression by 42% compared with letrozole alone in patients with ER-positive, HER2-negative advanced or metastatic breast cancer.
Long-Term Data Deepen Dabrafenib/Trametinib Benefit in Melanoma
The combination of dabrafenib and trametinib continued to demonstrate impressive overall survival and progression-free survival findings for patients with
-mutant metastatic melanoma in 3-year follow-up data from the phase III COMBI-d study.
Alectinib Could Represent First-Line Standard in ALK-Positive NSCLC
Alectinib improved progression-free survival by 66% compared with the current standard crizotinib as initial inhibitor therapy in patients with advanced or recurrent
-positive non–small cell lung cancer.
Long-Term Follow-up Sustains Frontline Nivolumab/Ipilimumab Benefit in Melanoma
At a minimum follow-up of 18 months, the combination of nivolumab and ipilimumab reduced the risk of disease progression by 58% compared with ipilimumab alone, and single-agent nivolumab lowered the risk of progression by 45% versus ipilimumab monotherapy in patients with advanced melanoma.
Binimetinib Shows Rare PFS Benefit in NRAS-Mutant Melanoma
The MEK inhibitor binimetinib reduced the risk of progression or death by 38% compared with dacarbazine in patients with
-mutant metastatic melanoma.
PD-L1 Inhibitor Avelumab Active in Advanced Mesothelioma
Avelumab demonstrated clinical activity in patients with advanced or unresectable mesothelioma, with an overall response rate of 14.3%.
Nivolumab Improves OS, ORR in Phase III Head and Neck Cancer Study
Treatment with single-agent nivolumab improved overall survival and objective response rates compared with investigator's choice of therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma.
Black Women Who Are BRCA Carriers Less Likely to Pursue Breast and Ovarian Cancer Risk Reduction
Young black women with breast cancer are much less likely to have BRCA testing or, if they carry a BRCA mutation, to undergo risk-reducing prophylactic mastectomy or salpingo-oophorectomy.
Despite Recommendations, Aggressive Cancer Treatment Still Common at End of Life
An analysis of over 28,000 patients younger than 65 with incurable cancers found that approximately three-fourths of them received aggressive care within the last 30 days of life and one-third died in the hospital.
Web App Boosts Survival for Lung Cancer Patients
Patients with lung cancer who participated in a web-based system for reporting and tracking their symptoms achieved dramatic gains in survival compared with individuals who were followed with typical protocols.
Cancer Drugs Less Affordable in Poorer Countries Despite Lower Prices
Researchers who set out to understand the affordability of cancer drugs across the globe concluded that lower prices in some poorer countries don’t equate to better access.
Dabrafenib/Trametinib Combo Highly Effective in BRAF-Mutant NSCLC
The combination of dabrafenib and trametinib was highly effective as a treatment for patients with
V600E-mutant non–small cell lung cancer.
Nivolumab Delivers Durable Responses in Hodgkin Lymphoma
Single-agent nivolumab induced responses in 66% of patients with classical Hodgkin lymphoma who had progressed following autologous stem cell transplant and brentuximab vedotin.
Nivolumab 5-Year OS Rate Passes 30% in Advanced RCC
About one third of patients with advanced renal cell carcinoma who were treated with single-agent nivolumab in the second-line setting or later were still alive at 4 and 5 years in long-term follow-up data from phase I and phase II clinical trials.
Atezolizumab Effective in First-Line Setting in Bladder Cancer
Patients with metastatic urothelial carcinoma who were ineligible for standard cisplatin-based chemotherapy achieved a 24% reduction in tumor size and had a median survival of 14.8 months after taking the immunotherapy agent atezolizumab (Tecentriq).
Extending AI Therapy Beyond 5 Years Reduces Recurrence in HR-Positive Breast Cancer
Women who extended their adjuvant therapy with an aromatase inhibitor to 10 years after treatment for their early-stage HR-positive breast cancer reduced their risk of recurrence by more than a third and experienced no new toxicities or worsening of quality of life.
Survival in Recurrent GBM Surpasses Historical Results with Gene Therapy
A novel antiangiogenic gene therapy, added to bevacizumab, led to significantly better overall survival in recurrent glioblastoma multiforme compared with historical patients treated with bevacizumab alone, a small phase II trial showed.
Novel Gastric Cancer Immunotherapy Scores Robust Phase II Results
IMAB362 reduced the risk of death or progression by approximately 50% when added to standard chemotherapy for patients with CLDN18.2-positive advanced gastric cancers.
Nivolumab/Ipilimumab Combo Active in Microsatellite Instability-High mCRC
Nivolumab (Opdivo) as a monotherapy and in combination with ipilimumab (Yervoy) demonstrated promising antitumor activity in patients with high microsatellite instability (MSI-H) metastatic colorectal cancer.
Rovalpituzumab Tesirine Shows Promising Efficacy for SCLC
Treatment with rovalpituzumab tesirine demonstrated single-agent activity and a manageable safety profile for patients with recurrent/refractory small cell lung cancer.
Daratumumab Combo Shows Unprecedented PFS Benefit in Multiple Myeloma
Adding daratumumab to bortezomib and dexamethasone reduced the risk of progression or death by 61%
and doubled response rates compared with the standard 2-drug regimen alone for patients with recurrent or refractory multiple myeloma.
Adding Temozolomide to Radiotherapy Is Effective and Tolerable in Older Adults With Glioblastoma
Adding temozolomide to short-course radiotherapy after surgery boosted overall survival by nearly 2 months, bringing 1-year survival rates up from 22.2% to 37.8% for elderly patients with glioblastoma.
Nivolumab/Ipilimumab Frontline Response Nears 60% in PD-L1+ NSCLC
Upfront treatment with the combination of nivolumab and ipilimumab demonstrated an objective response rate of 57% in patients with PD-L1-positive advanced non–small cell lung cancer.
Final Phase III Data Uphold CPX-351 Survival Benefit in AML
CPX-351 reduced the risk of death by 31% compared with cytarabine and daunorubicin (7+3) for older patients with high-risk, secondary AML.
Adding 4-1BB Agonist to Pembrolizumab Safe, Effective Across Solid Tumors
The combination of the 4-1BB agonist utomilumab and the PD-1 inhibitor pembrolizumab was safe and effective as a treatment for patients with advanced solid tumors.
Nivolumab Survival Benefit Sustained in Long-Term NSCLC Outcomes
Two-year follow-up data showed sustained improvements in overall survival with nivolumab in pretreated patients with either nonsquamous or squamous non–small cell lung cancer in updated findings from the phase III CheckMate-057 and -017 trials.
Nivolumab Safe, Effective in Early Stage Glioblastoma Study
Single-agent nivolumab demonstrated encouraging signs of activity with a mild adverse event profile for patients with recurrent glioblastoma multiforme.
Molecular Targeting Yields Responses in 12 Cancers in Off-Label Indications
Treating patients based on the presence of molecular abnormalities regardless of tumor type proved to be a promising strategy in an ongoing phase IIa umbrella basket study.
Large Study Gives Boost to Liquid Biopsy Testing for Mutations
The liquid biopsy testing method correlated closely with mutations described in databases and in some cases from tumor biopsies.
Patient-Driven Research Project Aims to Advance Metastatic Breast Cancer Treatment
Researchers are hoping that a new nationwide effort to encourage patients to share their tumor samples and clinical information will lead to new discoveries and better treatments.
Combining Atezolizumab With OX40 Agonist Shows Promise in Solid Tumors
A combination regimen of the PD-L1 inhibitor atezolizumab (Tecentriq) and the investigational OX40 agonist MOXR0916 was well tolerated and showed early signs of of antitumor activity in solid tumors.
Carfilzomib/Pomalidomide Regimen Warrants Further Investigation in Refractory Multiple Myeloma
A regimen consisting of carfilzomib, pomalidomide, and dexamethasone merits further investigation for the treatment of patients with multiple myeloma whose disease progresses while on lenalidomide in the earlier stages of disease.
Nivolumab/Ipilimumab Combination Active in Recurrent SCLC
Treatment with the combination of nivolumab and ipilimumab demonstrated a median overall survival of 7.7 months and a 1-year OS rate of 43% for patients with recurrent small cell lung cancer.
Study Confirms Adjuvant Intraperitoneal Chemotherapy Is Beneficial and Well Tolerated
Intraperitoneal chemotherapy is beneficial and tolerable, and physicians should present it as an option to women who have had successful cytoreductive surgery for their advanced epithelial ovarian cancer.
Abemaciclib Active Against HR+/HER2- Breast Cancer
The CDK4/6 inhibitor abemaciclib induced a response rate of nearly 20% in heavily pretreated patients with refractory, HR-positive, HER2-negative advanced breast cancer, according to findings from the phase II MONARCH 1 trial.
Isatuximab Monotherapy Effective for Heavily Pretreated Myeloma
The anti-CD38 monoclonal antibody isatuximab showed promising signs of activity as a single-agent for patients with heavily pretreated relapsed/refractory multiple myeloma.
Temozolomide Trial Shows Improved 5-Year Survival Rates in Anaplastic Glioma
Results from a phase III trial investigating the benefit of adjuvant temozolomide in combination with radiation therapy has the potential to be practice changing for a rare type of brain cancer.
Biosimilar Trastuzumab Matches Herceptin in Efficacy and Safety
A biosimilar version of trastuzumab demonstrated equivalent efficacy and safety to the FDA-approved branded drug in a randomized phase III study among patients with HER2-positive metastatic breast cancer.
Capecitabine Combo Improves Survival in Resected Pancreatic Cancer
The addition of capecitabine to standard adjuvant gemcitabine doubled 5-year overall survival (OS) rates for patients with pancreatic cancer whose tumors were surgically removed.
A Look at This Year's ASCO Pipeline
Immunotherapy agents targeting the PD-1/PD-L1 pathway will be the most robust area for news at the 2016 ASCO Annual Meeting, but there will be much new data about recently approved and novel anticancer drugs for clinicians to digest.
6 Potential Practice-Changers Top Kantar's ASCO List
Research into 6 drugs scheduled to be presented during the upcoming 2016 ASCO Annual Meeting stand out as the most noteworthy abstracts on the docket this year because of their potential to influence clinical practice in the near future.
Pembrolizumab 3-Year Survival Rate Hits 40% in Melanoma
Forty percent of patients with advanced melanoma who started taking pembrolizumab during the clinical trial that led to its initial approval were still alive after 3 years, with many responders in remission even after stopping treatment.
Stem Cell Transplant Continues to Show Benefit in 'Novel-Agent Era' of Multiple Myeloma
Early findings from a phase III clinical trial suggest that patients with multiple myeloma who receive upfront autologous stem cell transplant survive longer without disease progression than those who receive chemotherapy alone.
Tumor Location Linked to Survival Outcomes in Metastatic Colorectal Cancer
Survival outcomes in patients with metastatic colorectal cancer were significantly longer among those with tumors originating on the left versus the right side of the colon, according to a retrospective analysis of the phase III 80405 trial.
Early Integration of Palliative Care Improves Outcomes for Family Caregivers
Early palliative care integrated with oncology care benefits not only patients with cancer but also family caregivers.
Outcomes Better With Biomarker-Based Therapies in Phase I Studies
Outcomes were significantly better in clinical trials that utilized a biomarker-based treatment selection strategy compared with non-personalized approaches.
FDA Approvals in Myeloma, NETs, and of a Biosimilar, Priority Review in Ovarian Cancer, and More
Investigators Hope Glioma Trial of Eflornithine Will Clinch Approval
ASCO Partners With FDA to Incorporate Real-World Evidence Into Drug Decisions
Outlook in Treating Patients With Ovarian Cancer
Weighing Treatment Strategies in
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2019
Intellisphere, LLC. All Rights Reserved.